Related references
Note: Only part of the references are listed.Glioblastoma recurrent cells switch between ATM and ATR pathway as an alternative strategy to survive radiation stress
Ekjot Kaur et al.
MEDICAL ONCOLOGY (2022)
Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells
Qian-Li Ma et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2022)
Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1
Amirali B. Bukhari et al.
FRONTIERS IN ONCOLOGY (2022)
Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)
Li-Wei Wang et al.
MOLECULES (2022)
Set2 histone methyltransferase regulates transcription coupled-nucleotide excision repair in yeast
Kathiresan A. Selvam et al.
PLOS GENETICS (2022)
Oxidative Stress and Deregulated DNA Damage Response Network in Lung Cancer Patients
Dimitra T. Stefanou et al.
BIOMEDICINES (2022)
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers
Guillaume Beinse et al.
BRITISH JOURNAL OF CANCER (2022)
An mTOR and DNA-PK dual inhibitor CC-115 hinders non-small cell lung cancer cell growth
Fagui Chen et al.
CELL DEATH DISCOVERY (2022)
PARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
Xueting Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Targeting HER3-dependent activation of nuclear AKT improves radiotherapy of non-small cell lung cancer
Mahmoud Toulany et al.
RADIOTHERAPY AND ONCOLOGY (2022)
Multi-pathway DNA-repair reporters reveal competition between end-joining, single-strand annealing and homologous recombination at Cas9-induced DNA double-strand breaks
Bert van de Kooij et al.
NATURE COMMUNICATIONS (2022)
Signal pathways and precision therapy of small-cell lung cancer
Min Yuan et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)
Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase
Marika Saar et al.
MOLECULAR AND CLINICAL ONCOLOGY (2021)
Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer
Xing-mei Liang et al.
ACTA PHARMACOLOGICA SINICA (2021)
Activation of DNA damage response signaling in mammalian cells by ionizing radiation
Somnath Ghosh et al.
FREE RADICAL RESEARCH (2021)
An extending ATR-CHK1 circuitry: the replication stress response and beyond
Antoine Simoneau et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2021)
Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy
Francesca Esposito et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
Jin Hur et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
CRL4ADTL degrades DNA-PKcs to modulate NHEJ repair and induce genomic instability and subsequent malignant transformation
Maoxiao Feng et al.
ONCOGENE (2021)
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses
Erik H. Knelson et al.
CANCERS (2021)
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress
Anish Thomas et al.
CANCER CELL (2021)
Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study
Wenxian Wang et al.
LUNG CANCER (2021)
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors
Kasper Fugger et al.
SCIENCE (2021)
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
Ukhyun Jo et al.
MOLECULAR CANCER THERAPEUTICS (2021)
DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
Manni Wang et al.
ACTA PHARMACEUTICA SINICA B (2021)
Recent developments in the treatment of small cell lung cancer
Birgitta Hiddinga et al.
EUROPEAN RESPIRATORY REVIEW (2021)
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures
Miklos Diossy et al.
NPJ PRECISION ONCOLOGY (2021)
AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors
Kavya Ramkumar et al.
MOLECULAR CANCER RESEARCH (2021)
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors
Wenchao Ji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
DNA Damage Response and Oxidative Stress in Systemic Autoimmunity
Vassilis L. Souliotis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
DNA-PK Inhibitor, M3814, as a New Combination Partner of Mylotarg in the Treatment of Acute Myeloid Leukemia
Michael Carr et al.
FRONTIERS IN ONCOLOGY (2020)
Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)
Aaron C. Tan
THORACIC CANCER (2020)
Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models
Frank T. Zenke et al.
MOLECULAR CANCER THERAPEUTICS (2020)
M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
Zhuo-Xun Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Base excision repair and its implications to cancer therapy
Gabrielle J. Grundy et al.
GUARDIANS OF THE GENOME: DNA DAMAGE AND REPAIR (2020)
DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage
Thom G. A. Reuvers et al.
CANCERS (2020)
An update on the immune landscape in lung and head and neck cancers
Jennifer W. Carlisle et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer
Arishya Sharma et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
DNA Damage and Cancer Immunotherapy: A STING in the Tale
Timo Reislander et al.
MOLECULAR CELL (2020)
Dual mTOR/DNA-PK Inhibitor CC-115 Induces Cell Death in Melanoma Cells and Has Radiosensitizing Potential
Felix Burkel et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Methods to Study Intracellular Movement and Localization of the Nucleotide Excision Repair Proteins at the DNA Lesions in Mammalian Cells
Mihaela Robu et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Dual inhibition of DNA-PKcs and mTOR by CC-115 potently inhibits human renal cell carcinoma cell growth
Bing Zheng et al.
AGING-US (2020)
Unexpected Synergy Reveals New Therapeutic Strategy in SCLC
Benjamin J. Drapkin et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2019)
SIRT1 deacetylated and stabilized XRCC1 to promote chemoresistance in lung cancer
Neelum Aziz Yousafzai et al.
CELL DEATH & DISEASE (2019)
Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages-a single-center study
Marina Piljic Burazer et al.
DIAGNOSTIC PATHOLOGY (2019)
Epigenetic targeting of DNA repair in lung cancer
Benjamin H. Lok et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study
Taofeek K. Owonikoko et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Depletion of Akt1 and Akt2 Impairs the Repair of Radiation-Induced DNA Double Strand Breaks via Homologous Recombination
Tahereh Mohammadian Gol et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Circular RNA circNOL10 Inhibits Lung Cancer Development by Promoting SCLM1-Mediated Transcriptional Regulation of the Humanin Polypeptide Family
Aruo Nan et al.
ADVANCED SCIENCE (2019)
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models
Hannah C. Wise et al.
SCIENTIFIC REPORTS (2019)
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
Pamela Munster et al.
CANCER MANAGEMENT AND RESEARCH (2019)
DNA repair as an emerging target for COPD-lung cancer overlap
Catherine R. Sears
RESPIRATORY INVESTIGATION (2019)
Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness
Naomi Miyake et al.
YONAGO ACTA MEDICA (2019)
Global Epidemiology of Lung Cancer
Julie A. Barta et al.
ANNALS OF GLOBAL HEALTH (2019)
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Alan Ashworth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Theo A. Knijnenburg et al.
CELL REPORTS (2018)
Structural basis of DNA lesion recognition for eukaryotic transcription coupled nucleotide excision repair
Wei Wang et al.
DNA REPAIR (2018)
Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy
Tatsuya Nagano et al.
CELLS (2018)
A systematic review of targeted agents for non-small cell lung cancer
Hannah H. Vestergaard et al.
ACTA ONCOLOGICA (2018)
Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC
T. Mok et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Triparna Sen et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Targeting DNA Repair in Cancer : Beyond PARP Inhibitors
Jessica S. Brown et al.
CANCER DISCOVERY (2017)
The deubiquitinating enzyme Usp14 allosterically inhibits multiple proteasomal activities and ubiquitin-independent proteolysis
Hyoung Tae Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
A phase lb trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib
Teresa Moran et al.
LUNG CANCER (2017)
Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy
Victoria Dunne et al.
RADIOTHERAPY AND ONCOLOGY (2017)
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
Toshiya Tsuji et al.
ONCOTARGET (2017)
Lung Basal Stem Cells Rapidly Repair DNA Damage Using the Error-Prone Nonhomologous End-Joining Pathway
Clare E. Weeden et al.
PLOS BIOLOGY (2017)
The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
Brock J. Sishc et al.
CANCERS (2017)
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
Triparna Sen et al.
CANCER RESEARCH (2017)
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance
Sitian Yang et al.
BMC CANCER (2017)
Endogenous DNA Damage as a Source of Genomic Instability in Cancer
Anthony Tubbs et al.
CELL (2017)
Role of Deubiquitinating Enzymes in DNA Repair
Younghoon Kee et al.
MOLECULAR AND CELLULAR BIOLOGY (2016)
Exploiting DNA repair defects for novel cancer therapies
Dik C. van Gent et al.
MOLECULAR BIOLOGY OF THE CELL (2016)
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
Robert J. Cardnell et al.
PLOS ONE (2016)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
A. Bakr et al.
NUCLEIC ACIDS RESEARCH (2015)
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
Claudia Fumarola et al.
BIOCHEMICAL PHARMACOLOGY (2014)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients
C. M. Choi et al.
ANNALS OF ONCOLOGY (2012)
Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy
Ming Yin et al.
CANCER (2012)
Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy
Pek Keng Koh et al.
CANCER TREATMENT REVIEWS (2012)
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine- DNA Methyltransferase as a Potential Biomarker
M. Catherine Pietanza et al.
CLINICAL CANCER RESEARCH (2012)
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Peter Bouwman et al.
NATURE REVIEWS CANCER (2012)
Integrative computational biology for cancer research
Kristen Fortney et al.
HUMAN GENETICS (2011)
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Alex Chang
LUNG CANCER (2011)
Polymorphisms of Homologous Recombination Genes and Clinical Outcomes of Non-Small Cell Lung Cancer Patients Treated with Definitive Radiotherapy
Ming Yin et al.
PLOS ONE (2011)
Diaphragm adaptations in patients with COPD
Coen A. C. Ottenheijm et al.
RESPIRATORY RESEARCH (2008)
Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia
C Seedhouse et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
